As of now, there’s no definitive evidence that China or a Chinese entity is actively attempting to buy 23andMe. The genetic testing company filed for Chapter 11 bankruptcy on March 23, 2025, and has received court approval to sell its assets, including its valuable database of genetic information from over 15 million users. This has sparked speculation about potential buyers, including concerns about foreign entities like China acquiring the data.
Historically, there’s been some Chinese investment in 23andMe. For instance, WuXi Healthcare Ventures, a Chinese firm, held a minor stake (less than 1%) in 2021, but no current ownership by Chinese entities is confirmed. The company doesn’t operate in China or share data with Chinese organizations, according to available information. However, the bankruptcy process opens the door to any qualified bidder, and a Chinese company or shell corporation could theoretically participate if it meets the court’s requirements, such as agreeing to comply with 23andMe’s privacy policy and U.S. laws.
Concerns about China acquiring this data stem from national security fears, including the potential misuse of genetic information for bioweapons or surveillance. These worries have been echoed in posts on X and by some commentators, but they remain speculative. The U.S. government could intervene if a sale to a foreign entity raises security issues—similar to the TikTok divestment scenario—though no specific restrictions targeting China have been reported in this case yet.
While it’s possible for a Chinese entity to bid on 23andMe, there’s no concrete indication it’s happening, and any sale would face regulatory scrutiny. The process is ongoing, with final offers due by May 7, 2025, and a court hearing set for June 17, 2025, so more clarity may emerge soon.
Comments